Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Elutia (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix products, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Elutia (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix products, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21, 2024. The company's leadership team, including Dr. Randy Mills (President and CEO), Matt Ferguson (CFO), and Dr. Michelle LeRoux Williams (Chief Scientific Officer), will be available for one-on-one meetings with institutional investors during the event. Interested institutional investors can arrange meetings through their Canaccord representatives.
Details
News Market Reaction – ELUT
The recorded move for ELUT in the trading session of this news was +2.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson, Chief Financial Officer, and Dr. Michelle LeRoux Williams, Chief Scientific Officer, will participate in 1x1 investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024.
Institutional investors interested in meeting with management during the conference may reach out to their Canaccord representative.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.